Sugi Predict

Sugi Predict / Compounds / SCHEMBL19971486

SCHEMBL19971486

SCHEMBL19971486

O=C(O)c1cn(-c2ncc(F)cc2F)c2nc(N3CC[C@H](O)C3)c(F)cc2c1=O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 1/20 0.63
▸ EPHA2 P29317 1/20 0.55
▸ FLT4 P35916 1/20 0.55
▸ GSK3B P49841 1/20 0.55
▸ RARB P10826 1/20 0.55
▸ TBXAS1 P24557 1/20 0.55
▸ SLC6A3 Q01959 1/20 0.55
▸ LMNA P02545 4/20 0.51
▸ KDM4E B2RXH2 3/20 0.51
▸ ALDH1A1 P00352 2/20 0.51
▸ HSD17B10 Q99714 2/20 0.51
▸ POLB P06746 1/20 0.51
▸ HPGD P15428 1/20 0.51
▸ XBP1 P17861 1/20 0.51
▸ NFKB1 P19838 1/20 0.51
▸ HTT P42858 1/20 0.51
▸ NFKB2 Q00653 1/20 0.51
▸ RELA Q04206 1/20 0.51
▸ DPP4 P27487 6/20 0.46
▸ CYP2C9 P11712 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19986996 1.00 KMT2A (0.63) KMT2AEPHA2FLT4GSK3BRARB
SCHEMBL19971514 0.92 EPHA2 (0.61) KMT2AEPHA2FLT4GSK3BRARB
SCHEMBL19971407 0.89 KMT2A (0.65) KMT2AEPHA2FLT4GSK3BRARB
SCHEMBL19986854 0.89 KMT2A (0.65) KMT2AEPHA2FLT4GSK3BRARB
SCHEMBL29979989 0.89 KMT2A (0.65) KMT2AEPHA2FLT4GSK3BRARB
SCHEMBL19971402 0.89 EPHA2 (0.61) KMT2AEPHA2FLT4GSK3BRARB
SCHEMBL9536271 0.86 KMT2A (0.66) KMT2AEPHA2FLT4GSK3BRARB
SCHEMBL29991676 0.85 KMT2A (0.47) KMT2AEPHA2FLT4GSK3BRARB
SCHEMBL19987063 0.85 KMT2A (0.47) KMT2AEPHA2FLT4GSK3BRARB
SCHEMBL19987065 0.85 KMT2A (0.47) KMT2AEPHA2FLT4GSK3BRARB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115554294-A 7-substituted 1-arylnaphthyridine-3-carboxamides and their use 拜耳股份公司 2023-01-03 — — CN disclosed
CN-115477649-A 7-substituted 1-arylnaphthyridine-3-carboxamides and their use 拜耳股份公司 2022-12-16 — — CN disclosed
CN-115429798-A 7-substituted 1-arylnaphthyridine-3-carboxamides and their use 拜耳股份公司 2022-12-06 — — CN disclosed
US-11472803-B2 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof BAYER AKTIENGESELLSCHAFT (DE) 2022-10-18 — — US disclosed
CN-109689656-B 7-substituted 1-arylnaphthyridine-3-carboxamides and their use 拜耳股份公司 2022-10-04 — — CN disclosed
US-20220089591-A1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2022-03-24 — — US disclosed
EP-3512849-B1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDIN-3-CARBOXAMIDES AND THEIR USE BAYER AG (DE) 2021-06-23 — — EP disclosed
EP-3512849-B1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDIN-3-CARBOXAMIDES AND THEIR USE BAYER AG (DE) 2021-06-23 — — EP disclosed
US-10927109-B2 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof BAYER AKTIENGESELLSCHAFT (DE) 2021-02-23 — — US disclosed
US-10927109-B2 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof BAYER AKTIENGESELLSCHAFT (DE) 2021-02-23 — — US disclosed
US-20190263805-A1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2019-08-29 — — US disclosed
US-20190263805-A1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2019-08-29 — — US disclosed
EP-3512849-A1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF Bayer Aktiengesellschaft (DE) 2019-07-24 — — EP disclosed
WO-2018050510-A1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2018-03-22 — — WO disclosed
WO-2018050510-A1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2018-03-22 — — WO disclosed
EP-3296298-A1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDIN-3-CARBOXAMIDES AND THEIR USE Bayer Pharma Aktiengesellschaft (DE) 2018-03-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190263805-A1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF AADAC, GLS, NAT1 KMT2A 2845/4885EPHA2 4336/4885FLT4 1268/4885
US-20220089591-A1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF AADAC, GLS, NAT1 KMT2A 2845/4885EPHA2 4336/4885FLT4 1268/4885
US-10927109-B2 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof AADAC, GLS, NAT1 KMT2A 2845/4885EPHA2 4336/4885FLT4 1268/4885
US-11472803-B2 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof AADAC, GLS, NAT1 KMT2A 2845/4885EPHA2 4336/4885FLT4 1268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.